Company intelligence / Profile preview

Chongqing Sidemu Biotechnology Technology Co. Ltd.

Ownership: Private
Development stage: Phase 2

Overview

The company has a Phase I/II clinical trial (NCT04324996) for universal off-the-shelf NKG2D-ACE2 CAR-NK cells for COVID-19 therapy. Their technology includes NK cells secreting IL-15 superagonist and GM-CSF-neutralizing single-chain variable fragment (scFv)[1][4].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Cell therapyCAR-NK cells
Industry: Biotech

Drug pipeline

3 assets

haNK

Phase 2

Indications: Merkel cell carcinoma

2 more assets in the full pipeline.

Request access →

Partnerships

Chongqing Public Health Medical Center (trial sponsor)

Beyond the preview

Go deeper on Chongqing Sidemu Biotechnology Technology Co. Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chongqing Sidemu Biotechnology Technology Co. Ltd..

Explore the full profile